STRS Ohio’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-14,000
| Closed | -$665K | – | 2174 |
|
|
2025
Q3 | $665K | Hold |
14,000
| – | – | ﹤0.01% | 866 |
|
|
2025
Q2 | $747K | Buy |
14,000
+1,400
| +11% | +$63.6K | ﹤0.01% | 1030 |
|
|
2025
Q1 | $510K | Hold |
12,600
| – | – | ﹤0.01% | 1160 |
|
|
2024
Q4 | $351K | Hold |
12,600
| – | – | ﹤0.01% | 1330 |
|
|
2024
Q3 | $361K | Buy |
12,600
+12,400
| +6,200% | +$323K | ﹤0.01% | 1383 |
|
|
2024
Q2 | $4.69K | Hold |
200
| – | – | ﹤0.01% | 1936 |
|
|
2024
Q1 | $5K | Sell |
200
-1,800
| -90% | -$43.2K | ﹤0.01% | 1895 |
|
|
2023
Q4 | $46K | Buy |
2,000
+1,000
| +100% | +$19.7K | ﹤0.01% | 1785 |
|
|
2023
Q3 | $50K | Buy |
1,000
+600
| +150% | +$27.9K | ﹤0.01% | 1790 |
|
|
2023
Q2 | $18K | Buy |
+400
| New | +$18.3K | ﹤0.01% | 1889 |
|
|
2021
Q1 | – | Sell |
-2,600
| Closed | -$67K | – | 2169 |
|
|
2020
Q4 | $67K | Hold |
2,600
| – | – | ﹤0.01% | 1959 |
|
|
2020
Q3 | $80K | Buy |
2,600
+600
| +30% | +$21K | ﹤0.01% | 1883 |
|
|
2020
Q2 | $49K | Buy |
2,000
+700
| +54% | +$16K | ﹤0.01% | 1917 |
|
|
2020
Q1 | $27K | Hold |
1,300
| – | – | ﹤0.01% | 1871 |
|
|
2019
Q4 | $28K | Hold |
1,300
| – | – | ﹤0.01% | 1953 |
|
|
2019
Q3 | $29K | Buy |
+1,300
| New | +$30.3K | ﹤0.01% | 1948 |
|
Other funds holding AKRO
STRS Ohio's AKRO Position: Q4 2025 in Review
STRS Ohio sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 14,000 shares — an estimated $665K sold.
STRS Ohio first reported a position in AKRO in Q3 2019 and held it in 16 quarters. The position peaked at $747K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- STRS Ohio reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- STRS Ohio sold 14,000 Akero Therapeutics shares in Q4 2025, an estimated $665K.
- STRS Ohio first reported a position in Akero Therapeutics in Q3 2019 and held it in 16 quarters.
- STRS Ohio's Akero Therapeutics position peaked at $747K in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on STRS Ohio's 13F filing for Q4 2025, filed 2 Feb 2026.